Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia

Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia

Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD+) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD+ biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in precli...

Full description

Bibliographic Details
Main Authors: Bellotti, A. (Author), Biniecka, P. (Author), Duchosal, M.A (Author), ElMokh, O. (Author), Gallart-Ayala, H. (Author), Ivanisevic, J. (Author), Matsumoto, S. (Author), Nahimana, A. (Author), Nencioni, A. (Author), Piacente, F. (Author), Schaeuble, K. (Author), Stamenkovic, I. (Author)
Format: Article
Language:English
Published: Springer Nature 2022
Subjects:
Cell Line, Tumor
cytokine
Cytokines
Gastrointestinal Microbiome
human
Humans
intestine flora
leukemia
Leukemia
metabolism
NAD
neoplasm
Neoplasms
Niacinamide
nicotinamide
nicotinamide adenine dinucleotide
nicotinamide phosphoribosyltransferase
Nicotinamide Phosphoribosyltransferase
tumor cell line
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items